A dietary conjugated linoleic acid treatment that slows renal disease progression alters renal cyclooxygenase-2-derived prostanoids in the Han: SPRD-cy rat

Journal of Nutritional Biochemistry

Volumn 23, Issue 8, 2012, Pages 908-914

  Wakefield, Andrew P ^a   Ogborn, Malcolm R ^a,b   Ibrahim, Naser ^a   Aukema, Harold M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF NORTHERN BRITISH COLUMBIA   (Canada)

Author keywords

Conjugated linoleic acid; Cyclooxygenase 2; Kidney disease; Phospholipase A2; Prostanoid

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CONJUGATED LINOLEIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FAT INTAKE; KIDNEY CYST; MALE; NONHUMAN; RAT; STEADY STATE;

ANIMALS; CYCLOOXYGENASE 2; CYTOSOL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; KIDNEY; KIDNEY DISEASES; LINOLEIC ACIDS, CONJUGATED; MALE; PHOSPHOLIPASES A2; PROSTAGLANDINS; RATS; RATS, INBRED STRAINS;

RATTUS;

EID: 84864007209     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.04.016     Document Type: Article

References (56)

1. Belury M.A. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr 2002, 22:505-531.
2. Churruca I., Fernandez-Quintela A., Portillo M.P. Conjugated linoleic acid isomers: differences in metabolism and biological effects. Biofactors 2009, 35:105-111.
3. Bhattacharya A., Banu J., Rahman M., Causey J., Fernandes G. Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem 2006, 17:789-810.
4. Banni S., Angioni E., Casu V., et al. Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid. Carcinogenesis 1999, 20:1019-1024.
5. Iwakiri Y., Sampson D.A., Allen K.G. Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages. Prostaglandins Leukot Essent Fatty Acids 2002, 67:435-443.
6. Li Y., Watkins B.A. Conjugated linoleic acids alter bone fatty acid composition and reduce ex vivo prostaglandin E2 biosynthesis in rats fed n-6 or n-3 fatty acids. Lipids 1998, 33:417-425.
7. Bonventre J.V. The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol 1999, 10:404-412.
8. Hirabayashi T., Shimizu T. Localization and regulation of cytosolic phospholipase A(2). Biochim Biophys Acta 2000, 1488:124-138.
9. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
10. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-33160.
11. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992, 263:F181-F191.
12. Zhang M.Z., Sanchez Lopez P., McKanna J.A., Harris R.C. Regulation of cyclooxygenase expression by vasopressin in rat renal medulla. Endocrinology 2004, 145:1402-1409.
13. Zhang M.Z., Wang J.L., Cheng H.F., Harris R.C., McKanna J.A. Cyclooxygenase-2 in rat nephron development. Am J Physiol 1997, 273:F994-1002.
14. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504-2510.
15. Bakhle Y.S., Botting R.M. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 1996, 5:305.
16. Warford-Woolgar L., Peng C.Y., Shuhyta J., et al. Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys. Am J Physiol Renal Physiol 2006, 290:F897-904.
17. Harris R.C. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.
18. Brater DC, Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage 2002;23:S15,20; discussion S21-3.
19. Vitzthum H., Abt I., Einhellig S., Kurtz A. Gene expression of prostanoid forming enzymes along the rat nephron. Kidney Int 2002, 62:1570-1581.
20. Wang J.L., Cheng H.F., Shappell S., Harris R.C. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000, 57:2334-2342.
21. Sankaran D., Bankovic-Calic N., Ogborn M.R., Crow G., Aukema H.M. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 2007, 293:F821-F830.
22. Cheng H.F., Wang C.J., Moeckel G.W., Zhang M.Z., McKanna J.A., Harris R.C. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002, 62:929-939.
23. Dey A., Maric C., Kaesemeyer W.H., et al. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 2004, 107:561-570.
24. Blume C., Heise G., Muhlfeld A., et al. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999, 56:1770-1778.
25. Fujihara C.K., Antunes G.R., Mattar A.L., et al. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 2003, 64:2172-2181.
26. Sanchez P.L., Salgado L.M., Ferreri N.R., Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 1999, 34:848-853.
27. 2 release and interstitial injury in rat polycystic kidney disease. Kidney Int 2003, 64:1214-1221.
28. 2 and cyclooxygenases in polycystic kidney disease. FASEB J 2003, 17:298-300.
29. Reeves P.G., Nielsen F.H., Fahey G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123:1939-1951.
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
31. Peng C.Y., Sankaran D., Ogborn M.R., Aukema H.M. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. Exp Biol Med 2009, 234:737-743.
32. Harirforoosh S., Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009, 8:669-681.
33. Braden G.L., O'Shea M.H., Mulhern J.G., Germain M.J. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004, 19:1149-1153.
34. Perazella M.A. COX-2 selective inhibitors: analysis of the renal effects. Expert Opin Drug Saf 2002, 1:53-64.
35. Zoja C., Benigni A., Noris M., et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001, 60:653-663.
36. Purkerson M.L., Joist J.H., Yates J., Valdes A., Morrison A., Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci U S A 1985, 82:193-197.
37. Imig J.D. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 2000, 279:F965-F981.
38. Navar L.G., Inscho E.W., Majid S.A., Imig J.D., Harrison-Bernard L.M., Mitchell K.D. Paracrine regulation of the renal microcirculation. Physiol Rev 1996, 76:425-536.
39. Castellani S., Paniccia R., Di Serio C., et al. Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure. J Am Coll Cardiol 2003, 42:133-139.
40. Liu K.L., Belury M.A. Conjugated linoleic acid reduces arachidonic acid content and PGE2 synthesis in murine keratinocytes. Cancer Lett 1998, 127:15-22.
41. Storey A., Rogers J.S., McArdle F., Jackson M.J., Rhodes L.E. Conjugated linoleic acids modulate UVR-induced IL-8 and PGE2 in human skin cells: potential of CLA isomers in nutritional photoprotection. Carcinogenesis 2007, 28:1329-1333.
42. Kavanaugh C.J., Liu K.L., Belury M.A. Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. Nutr Cancer 1999, 33:132-138.
43. Li G., Barnes D., Butz D., Bjorling D., Cook M.E. 10t,12c-Conjugated linoleic acid inhibits lipopolysaccharide-induced cyclooxygenase expression in vitro and in vivo. J Lipid Res 2005, 46:2134-2142.
44. Nakanishi T., Koutoku T., Kawahara S., Murai A., Furuse M. Dietary conjugated linoleic acid reduces cerebral prostaglandin E(2) in mice. Neurosci Lett 2003, 341:135-138.
45. Whigham L.D., Higbee A., Bjorling D.E., Park Y., Pariza M.W., Cook M.E. Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1104-R1112.
46. McClelland S., Cox C., O'Connor R., et al. Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell. Atherosclerosis 2010.
47. Torres-Duarte A.P., Vanderhoek J.Y. Conjugated linoleic acid exhibits stimulatory and inhibitory effects on prostanoid production in human endothelial cells and platelets. Biochim Biophys Acta 2003, 1640:69-76.
48. Urquhart P., Parkin S.M., Rogers J.S., Bosley J.A., Nicolaou A. The effect of conjugated linoleic acid on arachidonic acid metabolism and eicosanoid production in human saphenous vein endothelial cells. Biochim Biophys Acta 2002, 1580:150-160.
49. Coen P., Cummins P., Birney Y., Devery R., Cahill P. Modulation of nitric oxide and 6-keto-prostaglandin F(1alpha) production in bovine aortic endothelial cells by conjugated linoleic acid. Endothelium 2004, 11:211-220.
50. Stachowska E., Dolegowska B., Dziedziejko V., et al. Prostaglandin E2 (PGE2) and thromboxane A2 (TXA2) synthesis is regulated by conjugated linoleic acids (CLA) in human macrophages. J Physiol Pharmacol 2009, 60:77-85.
51. Hwang D.M., Kundu J.K., Shin J.W., Lee J.C., Lee H.J., Surh Y.J. cis-9,trans-11-Conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt. Carcinogenesis 2007, 28:363-371.
52. Wang J.L., Cheng H.F., Zhang M.Z., McKanna J.A., Harris R.C. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998, 275:F613-F622.
53. Degner S.C., Kemp M.Q., Bowden G.T., Romagnolo D.F. Conjugated linoleic acid attenuates cyclooxygenase-2 transcriptional activity via an anti-AP-1 mechanism in MCF-7 breast cancer cells. J Nutr 2006, 136:421-427.
54. Banni S. Conjugated linoleic acid metabolism. Curr Opin Lipidol 2002, 13:261-266.
55. Ip C., Scimeca J.A. Conjugated linoleic acid and linoleic acid are distinctive modulators of mammary carcinogenesis. Nutr Cancer 1997, 27:131-135.
56. Sugano M., Tsujita A., Yamasaki M., Noguchi M., Yamada K. Conjugated linoleic acid modulates tissue levels of chemical mediators and immunoglobulins in rats. Lipids 1998, 33:521-527.